- Conditions
- Solid Tumor
- Interventions
- Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody
- Radiation · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 5,930
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancers
- Interventions
- LY2606368
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatocellular Carcinoma
- Interventions
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors
- Interventions
- Topotecan Liposomes Injection (TLI)
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
- Interventions
- ABBV-221
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • San Antonio, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 8
- States / cities
- Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
- Conditions
- Advanced Solid Tumor, DLBCL
- Interventions
- RNK05047
- Drug
- Lead sponsor
- Ranok Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • New York, New York
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
- Interventions
- Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 51
- States / cities
- Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Spartalizumab, Docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- semaxanib
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- TAS0612
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Advanced Cancers
- Interventions
- Temsirolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Solid Tumor
- Interventions
- YH42946
- Drug
- Lead sponsor
- Yuhan Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Islet Cell Tumor
- Interventions
- Everolimus, Pasireotide LAR
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • The Bronx, New York • Portland, Oregon + 1 more
- Conditions
- Solid Tumors
- Interventions
- Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 32
- States / cities
- Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
- Interventions
- Azacitidine, Pevonedistat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Chapel Hill, North Carolina
- Conditions
- Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 5 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
- Interventions
- [225]-FPI-2059, [111In]-FPI-2058
- Drug
- Lead sponsor
- 3B Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- enzastaurin, pemetrexed, carboplatin, bevacizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more
- Conditions
- Advanced Breast Cancer, Breast Cancer
- Interventions
- Neratinib, Lapatinib, Capecitabine
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Murrieta, California • Orange, California + 40 more
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
- Interventions
- Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Irinotecan
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more
- Conditions
- MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
- Interventions
- Anvumetostat, IDE397
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Denver, Colorado • Indianapolis, Indiana + 9 more
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma
- Interventions
- MK-0646, Gemcitabine, Erlotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas